Baird Financial Group
TEVA icon

Baird Financial Group’s Teva Pharmaceuticals TEVA Stock Holding History

Baird Financial Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,588
Closed -$157K – 1934
2021
Q4 		$157K Buy
+19,588
New +$177K ﹤0.01% 1838
2021
Q3 		– Sell
-11,527
Closed -$114K – 1926
2021
Q2 		$114K Buy
+11,527
New +$122K ﹤0.01% 1726
2019
Q4 		– Sell
-15,773
Closed -$109K – 1550
2019
Q3 		$109K Sell
15,773
-3,956
-20% -$30.3K ﹤0.01% 1479
2019
Q2 		$182K Sell
19,729
-17,725
-47% -$214K ﹤0.01% 1474
2019
Q1 		$587K Sell
37,454
-13,282
-26% -$234K ﹤0.01% 982
2018
Q4 		$782K Sell
50,736
-1,313
-3% -$26.9K 0.01% 869
2018
Q3 		$1.12M Buy
52,049
+8,248
+19% +$191K 0.01% 823
2018
Q2 		$1.06M Buy
43,801
+7,908
+22% +$161K 0.01% 817
2018
Q1 		$613K Buy
35,893
+9,689
+37% +$189K ﹤0.01% 957
2017
Q4 		$497K Sell
26,204
-113,390
-81% -$1.71M ﹤0.01% 1011
2017
Q3 		$2.46M Sell
139,594
-77,638
-36% -$1.75M 0.02% 568
2017
Q2 		$7.22M Sell
217,232
-25,622
-11% -$793K 0.06% 326
2017
Q1 		$7.79M Buy
242,854
+96,300
+66% +$3.29M 0.06% 304
2016
Q4 		$5.31M Buy
146,554
+28,373
+24% +$1.13M 0.05% 362
2016
Q3 		$5.44M Buy
118,181
+7,823
+7% +$408K 0.05% 350
2016
Q2 		$5.92M Buy
110,358
+34,177
+45% +$1.82M 0.05% 332
2016
Q1 		$4.08M Buy
76,181
+7,710
+11% +$452K 0.04% 390
2015
Q4 		$4.49M Buy
68,471
+3,850
+6% +$238K 0.04% 366
2015
Q3 		$3.65M Sell
64,621
-36,746
-36% -$2.38M 0.04% 391
2015
Q2 		$5.99M Buy
+101,367
New +$6.25M 0.06% 298

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Baird Financial Group's TEVA Position: Q1 2022 in Review

Baird Financial Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 19,588 shares — an estimated $157K sold.

Baird Financial Group first reported a position in TEVA in Q2 2015 and held it in 20 quarters. The position peaked at $7.79M in Q1 2017. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Baird Financial Group reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Baird Financial Group sold 19,588 Teva Pharmaceuticals shares in Q1 2022, an estimated $157K.
  • Baird Financial Group first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 20 quarters.
  • Baird Financial Group's Teva Pharmaceuticals position peaked at $7.79M in Q1 2017.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Baird Financial Group's 13F filing for Q1 2022, filed 13 May 2022.